News - AbbVie, Humira

Filter

Current filters:

AbbVieHumira

Popular Filters

AbbVie gains FDA orphan designation for Humira in uveitis

21-05-2014

The US Food and Drug Administration granted US drugmaker AbbVie’s blockbuster rheumatoid arthritis…

AbbVieHumiraOphthalmicsPharmaceuticalRegulationUSA

Global ulcerative colitis market to reach $6.6 billion by 2022

Global ulcerative colitis market to reach $6.6 billion by 2022

14-02-2014

The global ulcerative colitis market value will increase steadily over the coming years, increasing from…

AbbVieEntyvioGastro-intestinalsGlobalHumiraJohnson & JohnsonMarkets & MarketingPharmaceuticalRemicadeSimponi InjectionTakeda Pharmaceuticals

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Health Canada clears AbbVie’s Humira for UC

Health Canada clears AbbVie’s Humira for UC

28-11-2013

In what is now the eighth indication in Canada for its top-selling drug Humira (adalimumab), US drugmaker…

AbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

27-10-2013

Shares of AbbVie were up 2.4% at $49.09 in afternoon trading on the New York Stock Exchange on Friday,…

AbbVieFinancialHumiraPharmaceutical

Health Canada backs pediatric Humira for Crohn's

27-08-2013

US drugmaker AbbVie (NYSE: ABBV) says that Health Canada has approved its blockbuster rheumatoid arthritis…

AbbVieBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

AbbVie beats expectations, as Humira keeps growing

28-07-2013

US drugmaker AbbVie (NYSE: ABBV), spun-out from Abbott Laboratories from the start of this year, reported…

AbbVieFinancialHumiraPharmaceutical

Novartis' secukinumab demonstrates superiority to rival Enbrel in psoriasis study

08-07-2013

Swiss drug major Novartis (NOVN: VX) has announced results from a Phase III psoriasis study which showed…

AbbVieAmgenDermatologicalsEnbrelHumiraJanssen BiotechNovartisPharmaceuticalsecukinumabStelara Injectiontofacitinib

EULAR highlights: Celgene's apremilast; AbbVie's Humira; and Lilly's baricitinib

13-06-2013

Among highlights of the ongoing European League Against Rheumatism (EULAR) in Madrid, Spain, US biotech…

AbbVieAnti-Arthritics/RheumaticsapremilastbaricitinibBiotechnologyCelgeneEli LillyHumiramethotrexatePharmaceuticalResearch

Bristol-Myers Orencia equals Humira in head-to-head AMPLE RA study

12-06-2013

US drug major Bristol-Myers Squibb (NYSE: BMY) has announced the results of year two data from AMPLE…

AbbVieAnti-Arthritics/RheumaticsBristol-Myers SquibbHumiraOrenciaPharmaceuticalResearch

AbbVie's Humira cleared in EU for polyarticular juvenile idiopathic arthritis

03-04-2013

The European Commission has approved an extension of the European Union marketing authorization for US…

AbbVieAnti-Arthritics/RheumaticsEuropeHumiraPharmaceuticalRegulation

Positive Ph III results for AbbVie's Humira in pediatric Crohn's disease; five leukemia studies suspended

17-02-2013

AbbVie (NYSE: ABBV), the new spin-out from Abbott Laboratories, has announced the first long-term, patient-reported…

Abbott LaboratoriesAbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraOncologyPharmaceuticalResearch

Back to top